Trial Profile
Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Pfizer
- 30 Mar 2017 Results of retrospective data analysis two studies including this study published in the Targeted Oncology
- 18 Feb 2017 Results (n=53) assessing baseline characteristics associated with OS benefit from axitinib titration, presented at the 2017 Genitourinary Cancers Symposium
- 11 Oct 2016 Results of retrospective data analysis (n=402) of this trial and phase III (NCT00920816) trial presented at the 41st European Society for Medical Oncology Congress